Humacyte (HUMA) announced the publication of a new study comparing clinical outcomes of Symvess to autologous vein in the treatment of arterial trauma. The study was published in the American Association for the Surgery of Trauma’s Trauma Surgery & Acute Care Open Journal. The publication was entitled “Short-term Performance of Symvess Compared to External Control Data for Autologous Vein in Treatment of Extremity Arterial Trauma.” Compared to pre-existing patients in a trauma registry who were treated with autologous vein, patients treated with Symvess experienced similar short-term outcomes for patency, limb salvage, and infection.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte’s Phase 3 Trial: A New Era for Renal Disease Treatment?
- Humacyte price target lowered to $6 from $7 at BTIG
- Humacyte Announces $60M Stock and Warrants Offering
- Humacyte prices 28.4M shares at $2.11 in registered direct offering
- Promising Potential of Humacyte’s Symvess: Buy Rating Backed by Strong Efficacy and Market Position